Skip to main content
. 2021 Mar 23;15(3):e0008906. doi: 10.1371/journal.pntd.0008906

Table 1. Patient characteristics.

Groups Control Chagas’ disease DCM
0 NYHA I-II NYHA III-IV NYHA I-II NYHA III-IV
(n = 25) (n = 46) (n = 25) (n = 23) (n = 22) (n = 26)
Age (years) 53.9 ± 2.9 52.0 ± 1.5 50.6 ± 2.3 48.9 ± 1.9 49.8 ± 3.6 47.2 ± 2.4
Sex
 Male 12 11 10 13 14 16
 Female 13 35 15 10 8 10
SBP (mmHg) 121.0 ± 2.1 125.7 ± 2.1 110.3 ± 2.2### 98.7 ± 2.9***/### 112.8 ± 2.8# 95.9 ± 4.6***/###
DBP (mmHg) 76.4 ± 0.98 78.9 ± 1.2 73.3 ± 1.3 70.3 ± 1.8### 73.9 ± 1.5 70.8 ± 1.8###
HR (beats/min) 73.6 ± 1.2 69.5 ± 1.3 69.8 ± 2.1 75.0 ± 2.5 72.9 ± 2.0 83.2 ± 2.2**/###
ECG
Normal/Abnormal 25/0 13/33 0/25 0/23 0/22 0/26
Pacemaker 0 4 6 3 1 1
ECHO
 LVEF (%) 67.5 ± 1.1 37.8 ± 2.0### 24.5 ± 1.5### 37.2 ± 2.2### 23.4 ± 1.3###
 LVEF>50%/<50% 46/0 2/23 0/23 0/22 0/26
 LVDD (mm) 51.9 ± 1.0 62.7 ± 1.6### 70.9 ± 1.3### 64.7 ± 2.1### 74.9 ± 2.0###
 LVSD (mm) 32.6 ± 0.90 50.6 ± 1.8### 62.1 ± 1.3### 52.8 ± 2.1### 66.6 ± 2.1###
 LVEDV (ml) 131.5 ± 6.8 204.1 ± 12.0# 303.4 ± 20.2### 217.7 ± 16.8# 358.4 ± 36.3###
 LVESV (ml) 41.8 ± 3.0 109.8 ± 10.7## 209.5 ± 10.7### 137.5 ± 13.5### 256.9 ± 28.8###
Pharmacotherapy
 No medication 25 31 1 - - -
 ACEI - 3 22 21 20 15
 ß-blocker - 1 2 - 14 8
 ARB - - 1 1 2 8
 Amiodarone - 4 5 6 3 2
 Diuretic - 3 17 21 19 25
 Digoxin - 2 11 19 12 22
 Spironolactone - - 4 14 13 19
 Anticoagulant - 3 2 6 2 8

Data given as mean ± S.E.M.

**p < 0.01

***p < 0.001 vs. Control

#p < 0.05

##p < 0.01

###p < 0.001 vs. Chagas group 0. ACEI: Angiotensin converting enzyme inhibitor, ARB: Angiotensin receptor blocker, DBP: Diastolic blood pressure, ECG: Electrocardiogram, ECHO: Echocardiography parameters, HR: Heart rate, LVDD: Left ventricular diastolic diameter, LVEDV: Left ventricular end-diastolic volume, LVESV: Left ventricular end-systolic volume, LVSD: Left ventricular systolic diameter, ml: milliliter, mm: millimeter, SBP: Systolic blood pressure.